FIELD: medicine.
SUBSTANCE: invention refers to a combination therapy for treating cancer. Disclosed is the use of a pharmaceutical combination of the humanised B-Ly1 antibody, which is afucosylated and in which the fucose content is 60 % or less of the total amount of oligosaccharides (sugars) per Asn297, and -4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide, and 4-1[{(2R,3S,4R,5S)-4-(4-chloro-2-fluorophenyl)-3-(3-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino}-3-methoxybenzoic acid or a salt thereof for treating cancer.
EFFECT: invention provides high antiproliferative effect.
5 cl, 3 dwg, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | 2009 |
|
RU2506257C2 |
| SUBSTITUTED PYRROLIDIN-2-CARBOXAMIDE | 2011 |
|
RU2564022C2 |
| COMBINED THERAPY BASED ON CD20 ANTIBODY AND BTK INHIBITOR | 2014 |
|
RU2727650C2 |
| MDM2 PROTEIN DESTRUCTORS | 2017 |
|
RU2743432C2 |
| PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
| COMBINATION THERAPY BASED ON ANTI-CD20 ANTIBODY AND BTK INHIBITOR | 2021 |
|
RU2815679C2 |
| METHOD FOR PREDICTING THE THERAPEUTIC EFFECT OF AN LSD 1INHIBITOR BASED ON THE INSM1 EXPRESSION | 2018 |
|
RU2789449C2 |
| FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | 2014 |
|
RU2704112C2 |
| PYRROLIDINE DERIVATIVES | 2010 |
|
RU2562605C2 |
| DERIVATIVES OF 6-AMINO QUINAZOLINE OR 3-CYANOQUINOLINE, METHODS OF THEIR PRODUCTION AND THEIR APPLICATION AS INHIBITORS OF RECEPTOR TYROZINE KINASES EGFR OR HER-2 | 2010 |
|
RU2536102C2 |
